“Gold rush towards oncology” has major implications for pharma patent deal-making

A leading pharmaceuticals intelligence firm is predicting a sharp rise in the value of cancer therapy sales, and its chief forecaster recently told IAM of an ongoing “gold rush towards oncology” among life sciences companies. A key strategic focus…

Unlock unlimited access to all IAM content